Project Grant R01AI181676
Award Date
8/2/24
Completion Date
7/31/29
Dollars Obligated
$860K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop an HIV vaccine. The $228,825 award, effective August 9, 2024 through June 30, 2026, aims to synergize neutralizing and non-neutralizing antibody targets at the HIV/SIV viral spike apex. The research will 1) design and validate a vaccine immunogen focused on the V2B neutralization epitope, and 2)...
This $7,105,240 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will develop an HIV vaccine regimen that elicits both broadly neutralizing antibodies and high-quality T-cell responses. The research program, named OPTI-FLIP, combines investigations into cooperative antibody and T-cell immunity, as well as innovative strategies for generating follicular T cells and cytotoxic T...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to exploit glycan holes and sequence diversity of naturally occurring HIV envelope proteins to design vaccine immunogen panels for inducing broader neutralization breadth against HIV. The $742,463 award to the University of Washington will leverage bioinformatic tools, artificial intelligence, and in vitro...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $176,063 to the University of Hawaii to conduct research on designing and testing novel HIV vaccine immunogens. The goal is to develop immunogens that can guide the evolution of the VRC01 broadly neutralizing antibody lineage towards a mature phenotype capable of producing antibodies that can neutralize diverse HIV...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The $737,761 award will fund research to induce robust CD4 T follicular helper (Tfh) cells, which are essential for vigorous B cell activity within germinal centers and the production of persistent antibodies. The research will examine...
This $194,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop virus-like particles (VLPs) for a novel HIV-1 cure strategy. The project aims to use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent (the "shock") and then target the reactivated cells for elimination using adeno-associated virus (AAV) vectors expressing broadly...
This federal Project Grant award, totaling $794,045.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to study the host cellular drivers of class II cytokine-mediated viral control across different stages of HIV infection, from acute infection to antiretroviral therapy (ART) interruption. The key products and services to be delivered under this grant include: 1) implementing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $220,224 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Chicago. This grant supports computational investigations into the assembly, maturation, and uncoating processes of the HIV-1 virus. The research aims to enhance the mechanistic understanding of how viral RNA is packaged, which could aid in the design of future therapeutics targeting viral assembly and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,256 to support research aimed at eliciting broadly neutralizing antibodies (bNAbs) against HIV-1 through immunization approaches. The research, led by MD-PhD student Ashwin Skelly under the mentorship of Drs. Beatrice Hahn and Amelia Escolano at the University of Pennsylvania and Wistar Institute, will...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and evaluate a novel cure strategy for HIV-1 that combines small-molecule CD4-mimetic compounds (CD4MCs) with CD4-induced antibodies (CD4I Abs). The total funding amount is $1,314,572, awarded to Yale University with a period of performance from August 2024 to June 2029. The research project...